Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Adjuvant Capital is a venture capital firm founded to finance life science technologies that address high-burden public health challenges. Established with a mission to deploy capital in promising public health technologies, the firm operates from its offices in New York City and Zurich. Adjuvant Capital focuses on improving health outcomes in low- and middle-income countries while pursuing financial returns. The firm has a strong reputation for its commitment to social impact, ensuring that the technologies it supports are accessible to those in need. With a focus on innovative solutions, Adjuvant Capital has positioned itself as a key player in the biotech and healthcare sectors, raising multiple funds to support its investment strategy. The firm primarily invests in seed, Series A, and Series B stages, allowing it to engage with startups at various points in their development. Its leadership team comprises experienced professionals with deep expertise in life sciences and public health, further enhancing its ability to identify and support transformative technologies.
Adjuvant Capital invests in innovative technologies targeting neglected and high-burden infectious diseases, maternal and child health, nutrition, and reproductive and sexual health. The firm primarily makes preferred equity investments in technologies that have demonstrated safety and efficacy in humans, particularly those with compelling proof-of-concept data. This focus allows Adjuvant Capital to back companies that are not only financially promising but also socially impactful. The firm seeks to partner with entrepreneurs who are dedicated to addressing significant public health challenges, particularly in underserved populations. By concentrating on biotech and healthcare sectors, Adjuvant Capital aims to foster advancements that can lead to improved health outcomes globally. The firm’s geographic focus spans North America and Europe, reflecting its commitment to addressing health issues that affect diverse populations. Adjuvant Capital looks for founders who are innovative, resilient, and passionate about making a difference in public health, ensuring that their investments align with their mission of enhancing accessibility to vital health technologies.
Adjuvant Capital boasts a robust portfolio of notable companies that are making significant strides in the life sciences sector. Among its investments are **LimmaTech Biologics**, which focuses on vaccine development for antimicrobial resistance, and **Memo Therapeutics**, known for its antibody discovery technologies targeting various viruses. Other key portfolio companies include **Curevo Vaccine**, which is developing next-generation vaccines for varicella, and **Antiva Biosciences**, which is working on treatments for cervical lesions. The firm also supports **Pulmocide**, which is developing therapies for respiratory diseases, and **Excision BioTherapeutics**, known for its CRISPR therapies aimed at viral infections. Additionally, **Frontier Nutrition** is addressing malnutrition through fortified snacks, while **VitriVax** is innovating in vaccine thermostability technology. With a diverse range of investments, Adjuvant Capital is committed to supporting companies that are at the forefront of addressing critical health challenges, particularly in low- and middle-income countries.
To pitch Adjuvant Capital, please email yanatos@adjuvantcapital.com. Include a clear overview of your technology, its public health impact, and any proof-of-concept data. They welcome pitches that demonstrate innovation and a commitment to addressing critical health challenges.
Adjuvant Capital invests in companies at various stages, including seed, Series A, and Series B. This allows them to engage with startups as they develop and scale their innovative health technologies.
Founders can pitch Adjuvant Capital by sending an email to yanatos@adjuvantcapital.com. It is advisable to include a clear overview of the technology, its impact on public health, and any proof-of-concept data available.
The firm primarily focuses on the biotech and healthcare sectors, specifically targeting technologies that address neglected and high-burden infectious diseases, maternal and child health, nutrition, and reproductive and sexual health.
While specific check sizes are not disclosed, Adjuvant Capital invests across seed, Series A, and Series B stages, indicating a flexible approach to funding based on the needs of the startups they support.
Adjuvant Capital invests primarily in North America and Europe, with a strong emphasis on supporting health technologies that improve outcomes in low- and middle-income countries.
Founders interested in applying for investment should prepare a detailed pitch that outlines their technology, its potential impact, and any relevant data supporting its efficacy. They can reach out via the provided email address.
Adjuvant Capital is committed to supporting its portfolio companies by providing not only capital but also strategic guidance and access to a network of experts in the life sciences and public health sectors.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.